MA52976A - Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations - Google Patents

Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations

Info

Publication number
MA52976A
MA52976A MA052976A MA52976A MA52976A MA 52976 A MA52976 A MA 52976A MA 052976 A MA052976 A MA 052976A MA 52976 A MA52976 A MA 52976A MA 52976 A MA52976 A MA 52976A
Authority
MA
Morocco
Prior art keywords
substituted
tetrahydrothienopyridine derivatives
derivatives
substituted tetrahydrothienopyridine
tetrahydrothienopyridine
Prior art date
Application number
MA052976A
Other languages
English (en)
Inventor
Cyrille Kounde
Wei Lin Sandra Sim
Oliver Simon
Gang Wang
Hui Quan Yeo
Bryan Ks Yeung
Fumiaki Yokokawa
Bin Zou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67841114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52976(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA52976A publication Critical patent/MA52976A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052976A 2018-06-19 2019-06-18 Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations MA52976A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862687068P 2018-06-19 2018-06-19

Publications (1)

Publication Number Publication Date
MA52976A true MA52976A (fr) 2021-04-28

Family

ID=67841114

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052976A MA52976A (fr) 2018-06-19 2019-06-18 Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations

Country Status (24)

Country Link
US (3) US12012417B2 (fr)
EP (2) EP4169925B1 (fr)
JP (1) JP7328260B2 (fr)
KR (1) KR102835904B1 (fr)
CN (1) CN112313237A (fr)
AU (1) AU2019291488B2 (fr)
BR (1) BR112020025696A2 (fr)
CA (1) CA3100957A1 (fr)
CL (1) CL2020003248A1 (fr)
CR (1) CR20200618A (fr)
CU (1) CU20200100A7 (fr)
EA (1) EA202190046A1 (fr)
EC (1) ECSP20080995A (fr)
ES (1) ES2941946T3 (fr)
IL (1) IL279441B2 (fr)
JO (1) JOP20200326A1 (fr)
MA (1) MA52976A (fr)
MX (1) MX2020013852A (fr)
MY (1) MY201990A (fr)
PE (1) PE20210097A1 (fr)
PH (1) PH12020552185A1 (fr)
SA (1) SA520420809B1 (fr)
SG (1) SG11202012625PA (fr)
WO (1) WO2019244047A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945002B (zh) * 2017-08-01 2021-12-24 正大天晴药业集团股份有限公司 作为RORγ抑制剂的双环化合物
EP4169925B1 (fr) 2018-06-19 2025-11-19 Novartis AG Procédé pour la préparation de dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations
USD1006154S1 (en) * 2023-06-27 2023-11-28 Qiongfang Mao Cable crossover attachment
WO2025238553A1 (fr) 2024-05-14 2025-11-20 Novartis Ag Schémas posologiques pour n-(3-cyano-5-(cyclohexylméthyl)-6,6-diméthyl-4,5,6,7-tétrahydrothiéno[3,2-c]pyridin-2-yl)-2-(4-sulfamoylphényl)acétamide destiné à être utilisé dans le traitement ou la prévention d'une maladie ou d'un trouble du virus de la dengue
WO2025253267A1 (fr) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combinaison de mosnodenvir et d'analogues proches avec nitd-688 pour une utilisation dans le traitement et la prévention de la dengue

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US54472A (en) 1866-05-01 Improved blacking-brush
US5807A (en) 1848-09-26 Brake fob cabs
US8766A (en) 1852-02-24 Appabatus for lightening vessels
US6344A (en) 1849-04-17 Driving-bobbin
US4656A (en) 1846-07-24 Improvement in potato-plows
US498178A (en) 1893-05-23 William valentine leonard
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
TR199802136T2 (xx) 1996-04-23 2001-06-21 Vertex Pharmaceuticals Incorporated �MPDH enzimi inhibit�rleri olarak �re t�revleri.
ATE244717T1 (de) 1997-03-14 2003-07-15 Vertex Pharma Inhibitoren des impdh-enzyms
ES2405316T3 (es) 1999-03-19 2013-05-30 Vertex Pharmaceuticals Incorporated Inhibidores de la enzima IMPDH
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
CA2447897A1 (fr) 2001-05-21 2002-12-27 Monsanto Technology Llc Concentres pesticides contenant des agents de surface d'etheramine
US20030232994A1 (en) 2001-10-04 2003-12-18 Shao-Po Lu Bicyclic thiophene derivatives and combinatorial libraries thereof
CA2498399A1 (fr) 2002-09-12 2004-03-25 Merck & Co., Inc. Methode de traitement du diabete et d'etats associes
US7138529B2 (en) * 2003-04-16 2006-11-21 Hoffmann-La Roche Inc. Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
PL1753512T3 (pl) 2004-05-28 2009-03-31 4Sc Ag Tetrahydropirydotiofeny
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
EP1851229A1 (fr) 2005-02-09 2007-11-07 Nycomed GmbH Tetrahydropyridothiophenes permettant de traiter des maladies proliferatives telles que le cancer
WO2006084904A1 (fr) 2005-02-11 2006-08-17 Nycomed Gmbh Tetrahydropyridothiophenes en tant qu'agents antiproliferatifs pour le traitement du cancer
US7569600B2 (en) 2005-05-13 2009-08-04 Virochem Pharma Inc. Compounds and methods for the treatment of prevention of Flavivirus infections
JP2008542243A (ja) 2005-05-25 2008-11-27 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のテトラヒドロピリドチオフェン
JP2008542242A (ja) 2005-05-25 2008-11-27 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のテトラヒドロピリドチオフェン
US7932391B2 (en) 2005-09-08 2011-04-26 Zhejiang Hauhai Pharmaceutical Co., Ltd. Method for the preparation of clopidogrel and its analogues of methyl-tetrahydrothieno[3,2-C]pyridine acetate
JP2010500395A (ja) 2006-08-16 2010-01-07 ４エスツェー アクチェンゲゼルシャフト 癌治療のためのテトラヒドロピリドチオフェン誘導体
CA2660604A1 (fr) 2006-08-16 2008-02-21 4Sc Ag Derives de tetrahydrobenzothiophene
WO2008067222A1 (fr) 2006-11-28 2008-06-05 Kalypsys, Inc. Modulateurs hétérocycliques de tgr5
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010099166A1 (fr) * 2009-02-27 2010-09-02 Siga Technologies, Inc. Dérivés de thiénopyridine pour le traitement et la prévention d'infections par le virus de la dengue
US20130129677A1 (en) 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
JP5701655B2 (ja) * 2011-03-29 2015-04-15 奈良県 植物精油中のトロポロン類及び／又はフェノール類の金属錯体化方法
JP2014528412A (ja) 2011-09-30 2014-10-27 キネタ・インコーポレイテツド 抗ウイルス化合物
US10844051B2 (en) 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
CN108689987A (zh) * 2017-04-05 2018-10-23 浙江海正药业股份有限公司 一种磺胺类衍生物及其制备方法和用途
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CN110945002B (zh) 2017-08-01 2021-12-24 正大天晴药业集团股份有限公司 作为RORγ抑制剂的双环化合物
CN108191885B (zh) * 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用
EP4169925B1 (fr) 2018-06-19 2025-11-19 Novartis AG Procédé pour la préparation de dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations

Also Published As

Publication number Publication date
PH12020552185A1 (en) 2021-06-07
US20220073535A1 (en) 2022-03-10
KR20210022645A (ko) 2021-03-03
CU20200100A7 (es) 2021-08-06
EP4169925A2 (fr) 2023-04-26
EP3810613B1 (fr) 2023-01-11
EP4169925A3 (fr) 2023-06-14
ECSP20080995A (es) 2021-02-26
AU2019291488A1 (en) 2021-02-04
ES2941946T3 (es) 2023-05-26
JOP20200326A1 (ar) 2020-12-14
EP4169925B1 (fr) 2025-11-19
PE20210097A1 (es) 2021-01-12
CN112313237A (zh) 2021-02-02
SG11202012625PA (en) 2021-01-28
AU2019291488B2 (en) 2022-02-24
EP3810613A1 (fr) 2021-04-28
MX2020013852A (es) 2021-05-27
MY201990A (en) 2024-03-27
JP7328260B2 (ja) 2023-08-16
WO2019244047A1 (fr) 2019-12-26
IL279441B2 (en) 2023-06-01
CL2020003248A1 (es) 2021-07-09
US12012417B2 (en) 2024-06-18
CR20200618A (es) 2021-01-21
JP2021529159A (ja) 2021-10-28
US20240352030A1 (en) 2024-10-24
SA520420809B1 (ar) 2022-08-17
US20260070920A1 (en) 2026-03-12
CA3100957A1 (fr) 2019-12-26
US12331060B2 (en) 2025-06-17
IL279441A (en) 2021-01-31
BR112020025696A2 (pt) 2021-03-16
KR102835904B1 (ko) 2025-07-22
EA202190046A1 (ru) 2021-03-24

Similar Documents

Publication Publication Date Title
MA52483A (fr) Dérivés de gip et leurs utilisations
EP3706762A4 (fr) N4-hydroxycytidine et dérivés et leurs utilisations anti-virales
EP3841096A4 (fr) Dérivés de pyridinylméthylènepipéridine et leurs utilisations
EP3870579A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3908571A4 (fr) Dérivés de kétamine et leurs compositions
EP3746075A4 (fr) Inhibiteurs de gcn2 et leurs utilisations
EP3829649A4 (fr) Complexes de ciblage musculaire et leurs utilisations
EP3866789A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3694861A4 (fr) Composés hétérocycliques et leurs utilisations
EP3787607C0 (fr) Compositions de caroténoïdes et leurs utilisations
EP3886843A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3313530A4 (fr) Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci
MA52976A (fr) Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations
EP3938369A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3902530A4 (fr) Nanovaccins polymères et leurs utilisations
EP4017843A4 (fr) Dérivés de benzènesulfonamide et leurs utilisations
EP3697410A4 (fr) Dérivés de benzimidazole et leurs utilisations
EP3914357A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
MA52411A (fr) Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales
EP3323817A4 (fr) Dérivés d'aniline pyrimidine et leurs utilisations
EP3526215A4 (fr) Dérivés de n-acyléthanolamide et leurs utilisations
EP3870162A4 (fr) Inhibiteurs de ssao et leurs utilisations
EP3873912A4 (fr) Dérivés de benzodiazépine hétérocycliques fusionnés et leurs utilisations